BioStem Technologies, Inc. (BSEM)
BioStem Technologies, Inc. engages in the development, manufacturing, and commercialization of placental-derived allografts for advanced wound care and regenerative therapies in the United States. It offers Vendaje, a structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje AC, a thicker structural tissue allograft used as a protective covering for soft tissue wounds; Vendaje OPTIC, a structural tissue allograft used as a protective covering during the repair of ocular surfaces; American Amnion AC, a human connective tissue matrix for homologous use; and American Amnion, a human connective tissue matrix for homologous use. The company was formerly known as Caribbean International Holdings Inc. and changed its name to BioStem Technologies, Inc. in August 2014. BioStem Technologies, Inc. was incorporated in 2006 and is based in Fort Lauderdale, Florida.
Sector: Biological Products, (No Diagnostic Substances)
Industry: Biotechnology
BioStem Technologies, Inc.
Trials need funding. See this company's dilution risk and cash position.
- Not applicableWithdrawn
A Controlled Prospective Treatment Study to Evaluate the Efficacy of Vendaje.
Vendaje
Diabetic Foot Ulcer
NCT06150209Enrollment0StartJul 2024est.Primary CompletionDec 2024est.CompletionJun 2025est. - Not applicableCompleted
A Prospective Trial of Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AC
BR-AC, Standard Care
Diabetic Foot Ulcer
NCT06511596Enrollment71StartSep 2024Primary CompletionDec 2025CompletionDec 2025 - Not applicableCompleted
Non-healing Diabetic Foot Ulcers Treated With Standard Care With or Without BR-AM
BR-AM, Standard Care
Non-infected Diabetic Foot Ulcer, Diabetic Foot +3
NCT06565156Enrollment72StartOct 2024Primary CompletionNov 2025CompletionApr 2026 - Not applicableActive, not recruiting
Non-healing Venous Leg Ulcers Treated With Standard Care With or Without BR-AC
BR-AC, Standard Care
Non-infected Venous Leg Ulcer, Venous Leg Ulcer +3
NCT06811909Enrollment71StartFeb 2025Primary CompletionAug 2026CompletionOct 2026est.
| Drug / Therapy | Link | ||
|---|---|---|---|
| Not applicable | Withdrawn | Vendaje | NCT06150209 |
| Not applicable | Completed | BR-AC, Standard Care | NCT06511596 |
| Not applicable | Completed | BR-AM, Standard Care | NCT06565156 |
| Not applicable | Active, not recruiting | BR-AC, Standard Care | NCT06811909 |